Prakt. lékáren. 2015; 11(1): 25-28

Patient with liver and gallbladder disorder in pharmacy

Tereza Hendrychová1, Josef Malý2,3
1 Lékárna U zlatého lva, Dobruška
2 Katedra sociální a klinické farmacie, Farmaceutická fakulta UK v Hradci Králové
3 Nemocniční lékárna FN Motol, Praha

The present paper is focused on the selected aspects related to the involvement of pharmacist in care of patients with liver and gallbladder

disorders. The largest space is dedicated to non-pharmacological approaches and rational use of hepatoprotective drugs.

Keywords: self-medication, liver, gallbladder, non-pharmacological treatment, hepatoprotective drugs

Published: February 26, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hendrychová T, Malý J. Patient with liver and gallbladder disorder in pharmacy. Praktické lékárenství. 2015;11(1):25-28.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brodanová M. Farmakoterapie jaterních chorob in Marek J, a kol. Farmakoterapie vnitřních nemocí. Praha: Grada Publishing, a. s. 2005, 773.
    2. Databáze registrovaných léčivých přípravků SÚKL [online]. [citováno 6. 1. 2015]. URL: http://www.sukl.cz/modules/medication/search.php.
    3. Suchopár J, Kotlářová L, Végh V, a kol. Volně prodejné přípravky v praxi lékárníka a lékaře. Praha: Edukafarm, 2011, 478.
    4. Malý J, Rudolf K. Možnosti samoléčby u pacientů s dyspepsií, poruchami trávení a pálením žáhy v lékárně. Prakt lékáren 2011; 7(3): 138-143.
    5. Červený P. Polékové poškození jater. Prakt lékáren 2013; 9(3): 123-126.
    6. Brůha R, Dvořák K, Petrtýl J, Švestka T. Alkoholové poškození jater. Med Praxi 2009; 6(3): 144-146.
    7. Svačina Š. Dieta při chorobách žlučníku, pankreatu a jater in Klinická dietologie. Praha: Grada, 2008, 381.
    8. Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment. Drugs 2012; 72: 1645-1669. Go to original source... Go to PubMed...
    9. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12: 133-141. Go to original source... Go to PubMed...
    10. Hamilton JP, Goldberg E, Chopra S. Management of pain in patients with advanced chronic liver disease or cirrhosis. [online]. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. [citováno 6. 1. 2015].
    11. Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. World Gastroenterol 2011; 17(18): 2288-2301. Go to original source... Go to PubMed...
    12. Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Altern Med Rev 2011; 16(3): 239-249.
    13. Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 1998; 3(6): 410-421.
    14. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012; 78: 1458-1477. Go to original source... Go to PubMed...
    15. Rainone F. Milk thistle. Am Fam Physician 2005; 72(7): 1285-1288. Go to PubMed...
    16. Autor neuveden. Silybin-phosphatidylcholine complex. Monograph. Altern Med Rev 2009; 14(4): 385-390.
    17. Rambaldi A, Jacobs BP, Gluud C. No evidence supporting or refusing milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007; 4: CD003620. revize 2009. Go to original source... Go to PubMed...
    18. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 2002; 113(6): 506-515. Go to original source... Go to PubMed...
    19. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: Review of the evidence of efficacy. Clin Gastroenterol Hepatol 2007; 5: 408-416. Go to original source... Go to PubMed...
    20. Brůha R. Hepatoprotektivní látky v běžné praxi. Remedia 2011; 21: 376-379.
    21. Enjalbert F, Rapior S, Nouguier-Soulé J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002; 40(6): 715-757. Go to original source... Go to PubMed...
    22. Liu JP. Manheimer E, Tsunami K, Gluud C. Medicinal herbs for hepatitis C virus infection. Cochrane Database Syst Rev 2001; 4: CD003183. revize 2009. Go to original source... Go to PubMed...
    23. Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: A meta-analysis of randomized controlled trials. Biomed Res Int 2014; Art. ID 941085. Go to original source...
    24. Brůha R. Účelná farmakoterapie jaterních chorob v běžné praxi. Med Praxi 2012; 9(10): 379-381.
    25. Rambaldi A, Gluud C. No evidence to support or refute S-adenosyl-L-methionine for alcoholic liver disease. Cochrane Database Syst Rev 2006; 2: CD002235. revize 2009. Go to original source... Go to PubMed...
    26. Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140. Go to original source... Go to PubMed...
    27. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12: CD000551. Go to original source... Go to PubMed...
    28. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for liver disease related to cystic fibrosis. Cochrane Database Syst Rev 2012; 10: CD000222. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.